August 31, 2016 8:58 PM ET


Company Overview of Tinea Pharmaceuticals, Inc.

Company Overview

Tinea Pharmaceuticals, Inc., a biopharmaceutical company, develops products for the treatment of onychomycosis or fungal infections of the toenail and nail bed. Its Luliconazole is a topical antifungal agent against a range of pathogens, including Trichophyton rubrum, Trichophyton mentagrophytes, and yeasts. The company was formerly known as Topica Pharmaceuticals, Inc. and changed its name to Tinea Pharmaceuticals, Inc. in September 2010. The company was founded in 2004 and is based in Palo Alto, California.

435 Tasso Street

Suite 325

Palo Alto, CA 94301-1555

United States

Founded in 2004



Key Executives for Tinea Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 55
Chief Financial Officer
Senior Vice President of Clinical Development and Operations
Senior Vice President of Regulatory & Quality
General Counsel and Secretary
Age: 66
Compensation as of Fiscal Year 2016.

Tinea Pharmaceuticals, Inc. Key Developments

TOPICA Announces 10% Luliconazole Program Ready for Phase 3 Development for Onychomycosis Based on Positive Phase 2 Results

TOPICA Pharmaceuticals, Inc. announced that it’s ready to advance its 10% solution of luliconazole into Phase 3 development based on positive results from its Phase 2 SOLUTION Study. The company met with the FDA for an End of Phase 2 Meeting to discuss the company’s future Phase 3 plans and has determined that no additional pre-clinical work is necessary to support a New Drug Application. Based on the Phase 2 trial results and the positive End of Phase 2 Meeting, Topica is seeking a partner to advance 10% luliconazole into Phase 3 studies to pursue approval in its licensed territories of the Americas and Europe. Topica’s SOLUTION Study enrolled 334 patients at 28 clinical research sites across the U.S. Study participants were randomized (2:2:1:1) to one of four arms: 10% luliconazole applied once daily for 48 weeks, 10% luliconazole applied once daily for 12 weeks followed by once weekly treatment for 36 weeks, or one of two matched vehicle control arms. The primary endpoint was complete cure at week 52, which is the same endpoint used in recent Phase 3 trials to support FDA approval.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tinea Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at